Skip to main content

Articles

Page 5 of 24

  1. It is currently unknown whether exergaming is efficacious in people with major neurocognitive disorder (MNCD) residing in long-term care facilities. This pilot randomized controlled trial (RCT) explored the ef...

    Authors: Nathalie Swinnen, Mathieu Vandenbulcke, Eling D. de Bruin, Riekje Akkerman, Brendon Stubbs, Joseph Firth and Davy Vancampfort
    Citation: Alzheimer's Research & Therapy 2021 13:70
  2. To investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.

    Authors: Cécile Tissot, Andréa L. Benedet, Joseph Therriault, Tharick A. Pascoal, Firoza Z. Lussier, Paramita Saha-Chaudhuri, Mira Chamoun, Melissa Savard, Sulantha S. Mathotaarachchi, Gleb Bezgin, Yi-Ting Wang, Jaime Fernandez Arias, Juan Lantero Rodriguez, Anniina Snellman, Nicholas J. Ashton, Thomas K. Karikari…
    Citation: Alzheimer's Research & Therapy 2021 13:69
  3. Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer’s disease (AD) pathology in the form of AD-relate...

    Authors: Claudia Cicognola, Shorena Janelidze, Joakim Hertze, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2021 13:68
  4. A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the popul...

    Authors: Santiago Bullich, Núria Roé-Vellvé, Marta Marquié, Susan M. Landau, Henryk Barthel, Victor L. Villemagne, Ángela Sanabria, Juan Pablo Tartari, Oscar Sotolongo-Grau, Vincent Doré, Norman Koglin, Andre Müller, Audrey Perrotin, Aleksandar Jovalekic, Susan De Santi, Lluís Tárraga…
    Citation: Alzheimer's Research & Therapy 2021 13:67
  5. Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with...

    Authors: Seong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C. Kim, Jin Se Park, Jee-Young Lee, Sangjae Kim and Kyu-Yong Lee
    Citation: Alzheimer's Research & Therapy 2021 13:66
  6. To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory clin...

    Authors: Christopher Clark, Piotr Lewczuk, Johannes Kornhuber, Jonas Richiardi, Bénédicte Maréchal, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg and Julius Popp
    Citation: Alzheimer's Research & Therapy 2021 13:65
  7. To explore the utility of the International Working Group (IWG)-1 criteria in recruitment for Alzheimer’s disease (AD) clinical trials, we applied the more recently proposed research diagnostic criteria to ind...

    Authors: Anna Rosenberg, Alina Solomon, Hilkka Soininen, Pieter Jelle Visser, Kaj Blennow, Tobias Hartmann and Miia Kivipelto
    Citation: Alzheimer's Research & Therapy 2021 13:64
  8. Missing data can complicate the interpretability of a clinical trial, especially if the proportion is substantial and if there are different, potentially outcome-dependent causes.

    Authors: Floor M. van Oudenhoven, Sophie H. N. Swinkels, Hilkka Soininen, Miia Kivipelto, Tobias Hartmann and Dimitris Rizopoulos
    Citation: Alzheimer's Research & Therapy 2021 13:63
  9. New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of G...

    Authors: Shifu Xiao, Piu Chan, Tao Wang, Zhen Hong, Shuzhen Wang, Weihong Kuang, Jincai He, Xiaoping Pan, Yuying Zhou, Yong Ji, Luning Wang, Yan Cheng, Ying Peng, Qinyong Ye, Xiaoping Wang, Yuncheng Wu…
    Citation: Alzheimer's Research & Therapy 2021 13:62
  10. Dementia is a progressive neurocognitive disease with a substantial social burden. No apparent breakthroughs in treatment options have emerged so far; thus, disease prevention is essential for at-risk populati...

    Authors: Yoo Jin Jang, Cinoo Kang, Woojae Myung, Shinn-Won Lim, Young Kyung Moon, Ho Kim and Doh Kwan Kim
    Citation: Alzheimer's Research & Therapy 2021 13:61
  11. Generative adversarial networks (GAN) can produce images of improved quality but their ability to augment image-based classification is not fully explored. We evaluated if a modified GAN can learn from magneti...

    Authors: Xiao Zhou, Shangran Qiu, Prajakta S. Joshi, Chonghua Xue, Ronald J. Killiany, Asim Z. Mian, Sang P. Chin, Rhoda Au and Vijaya B. Kolachalama
    Citation: Alzheimer's Research & Therapy 2021 13:60
  12. Impaired axonal transport may contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) and Down syndrome (DS). Axonal transport is a complex process in which specific mo...

    Authors: Xu-Qiao Chen, Utpal Das, Gooho Park and William C. Mobley
    Citation: Alzheimer's Research & Therapy 2021 13:59
  13. Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide....

    Authors: Emily B. Button, Wai Hang Cheng, Carlos Barron, Honor Cheung, Asma Bashir, Jennifer Cooper, Jasmine Gill, Sophie Stukas, David C. Baron, Jerome Robert, Elyn M. Rowe, Peter A. Cripton and Cheryl L. Wellington
    Citation: Alzheimer's Research & Therapy 2021 13:58
  14. Regenerative therapies to mitigate Alzheimer’s disease (AD) neuropathology have shown very limited success. In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells h...

    Authors: Lauren A. Apodaca, Al Anoud D. Baddour, Camilo Garcia Jr, Leila Alikhani, Erich Giedzinski, Ning Ru, Anshu Agrawal, Munjal M. Acharya and Janet E. Baulch
    Citation: Alzheimer's Research & Therapy 2021 13:57
  15. 27-Hydroxycholesterol (27-OH), the main circulating oxysterol in humans and the potential missing link between peripheral hypercholesterolemia and Alzheimer’s disease (AD), has not been investigated previously...

    Authors: Anna Sandebring-Matton, Julen Goikolea, Ingemar Björkhem, Laura Paternain, Nina Kemppainen, Tiina Laatikainen, Tiia Ngandu, Juha Rinne, Hilkka Soininen, Angel Cedazo-Minguez, Alina Solomon and Miia Kivipelto
    Citation: Alzheimer's Research & Therapy 2021 13:56
  16. Single-nucleotide polymorphisms (SNPs) identified by genome-wide association studies only explain part of the heritability of Alzheimer’s disease (AD). Epistasis has been considered as one of the main causes o...

    Authors: Hui Wang, David A. Bennett, Philip L. De Jager, Qing-Ye Zhang and Hong-Yu Zhang
    Citation: Alzheimer's Research & Therapy 2021 13:55
  17. Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer’s disease (AD) is important for the understanding of disease pathophysiology and also crucial to be ab...

    Authors: Julia Remnestål, Sofia Bergström, Jennie Olofsson, Evelina Sjöstedt, Mathias Uhlén, Kaj Blennow, Henrik Zetterberg, Anna Zettergren, Silke Kern, Ingmar Skoog, Peter Nilsson and Anna Månberg
    Citation: Alzheimer's Research & Therapy 2021 13:54
  18. The DEmEntia with LEwy bOdies Project (DEvELOP) aims to phenotype patients with dementia with Lewy bodies (DLB) and study the symptoms and biomarkers over time. Here, we describe the design and baseline result...

    Authors: M. van de Beek, I. van Steenoven, J. J. van der Zande, I. Porcelijn, F. Barkhof, C. J. Stam, P. G. H. M. Raijmakers, P. Scheltens, C. E. Teunissen, W. M. van der Flier and A. W. Lemstra
    Citation: Alzheimer's Research & Therapy 2021 13:53
  19. Brain energy metabolism is impaired in Alzheimer’s disease (AD), which may be mitigated by a ketogenic diet. We conducted a randomized crossover trial to determine whether a 12-week modified ketogenic diet imp...

    Authors: Matthew C. L. Phillips, Laura M. Deprez, Grace M. N. Mortimer, Deborah K. J. Murtagh, Stacey McCoy, Ruth Mylchreest, Linda J. Gilbertson, Karen M. Clark, Patricia V. Simpson, Eileen J. McManus, Jee-Eun Oh, Satish Yadavaraj, Vanessa M. King, Avinesh Pillai, Beatriz Romero-Ferrando, Martijn Brinkhuis…
    Citation: Alzheimer's Research & Therapy 2021 13:51
  20. Dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) are recognised to be under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed. We aim...

    Authors: A. Surendranathan, J. Kane, A. Bentley, S. Barker, R. McNally, C. Bamford, J.-P. Taylor, A. Thomas, I. McKeith, D. Burn and J. T. O’Brien
    Citation: Alzheimer's Research & Therapy 2021 13:50
  21. Previous research has described distinct subtypes of Alzheimer’s disease (AD) based on the differences in regional patterns of brain atrophy on MRI. We conducted a data-driven exploration of distinct AD neurod...

    Authors: Fedor Levin, Daniel Ferreira, Catharina Lange, Martin Dyrba, Eric Westman, Ralph Buchert, Stefan J. Teipel and Michel J. Grothe
    Citation: Alzheimer's Research & Therapy 2021 13:49
  22. The presence of ß-amyloid (Aß) in the brain can be identified using amyloid PET. In clinical practice, the amyloid PET is interpreted based on dichotomous visual rating, which renders focal Aß accumulation be ...

    Authors: Si Eun Kim, Byungju Lee, Hyemin Jang, Juhee Chin, Ching Soong Khoo, Yeong Sim Choe, Ji Sun Kim, Sung Hoon Kang, Hang-Rai Kim, Song Hwangbo, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang…
    Citation: Alzheimer's Research & Therapy 2021 13:48
  23. Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is stil...

    Authors: Grazia Daniela Femminella, Nicholas R. Livingston, Sanara Raza, Thalia van der Doef, Eleni Frangou, Sharon Love, Gail Busza, Valeria Calsolaro, Stefan Carver, Clive Holmes, Craig W. Ritchie, Robert M. Lawrence, Brady McFarlane, George Tadros, Basil H. Ridha, Carol Bannister…
    Citation: Alzheimer's Research & Therapy 2021 13:47
  24. Recognizing clinical manifestations heralding the development of Alzheimer’s disease (AD)-related cognitive impairment could improve the identification of individuals at higher risk of AD who may benefit from ...

    Authors: Oriol Grau-Rivera, Irene Navalpotro-Gomez, Gonzalo Sánchez-Benavides, Marc Suárez-Calvet, Marta Milà-Alomà, Eider M. Arenaza-Urquijo, Gemma Salvadó, Aleix Sala-Vila, Mahnaz Shekari, José Maria González-de-Echávarri, Carolina Minguillón, Aida Niñerola-Baizán, Andrés Perissinotti, Maryline Simon, Gwendlyn Kollmorgen, Henrik Zetterberg…
    Citation: Alzheimer's Research & Therapy 2021 13:46
  25. Dysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers which are crucial ...

    Authors: Simone M. Crivelli, Qian Luo, Jo A.A. Stevens, Caterina Giovagnoni, Daan van Kruining, Gerard Bode, Sandra den Hoedt, Barbara Hobo, Anna-Lena Scheithauer, Jochen Walter, Monique T. Mulder, Christopher Exley, Matthew Mold, Michelle M. Mielke, Helga E. De Vries, Kristiaan Wouters…
    Citation: Alzheimer's Research & Therapy 2021 13:45
  26. In recent years, excellent results have suggested an association between the “brain-gut” axis and Alzheimer’s disease (AD) progression, yet the role of the “brain-gut” axis in AD pathogenesis still remains obs...

    Authors: Xinru Gu, Junyi Zhou, Yanyan Zhou, Hongjie Wang, Nan Si, Wei Ren, Wei Zhao, Xiaorui Fan, Wenya Gao, Xiaolu Wei, Jian Yang, Baolin Bian and Haiyu Zhao
    Citation: Alzheimer's Research & Therapy 2021 13:44
  27. The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their ef...

    Authors: Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Aaron Jackson, Jodi D. Edwards, Joel Ramirez, Mario Masellis, Richard H. Swartz, Nathan Herrmann, Krista L. Lanctôt, Sandra E. Black and Walter Swardfager
    Citation: Alzheimer's Research & Therapy 2021 13:43
  28. PET imaging of glucose metabolism has revealed presymptomatic abnormalities in genetic FTD but has not been explored in MAPT P301L mutation carriers. This study aimed to explore the patterns of presymptomatic hyp...

    Authors: Mica T. M. Clarke, Frédéric St-Onge, Jean-Mathieu Beauregard, Martina Bocchetta, Emily Todd, David M. Cash, Jonathan D. Rohrer and Robert Laforce Jr
    Citation: Alzheimer's Research & Therapy 2021 13:42
  29. Observational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer’s disease (AD); however, these findings may be biased by confounding and reverse...

    Authors: Ya-Nan Ou, Yu-Xiang Yang, Xue-Ning Shen, Ya-Hui Ma, Shi-Dong Chen, Qiang Dong, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:41
  30. The neuropathological hallmarks of Alzheimer’s disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition pr...

    Authors: Yanxing Chen, Shuai Zhao, Ziqi Fan, Zheyu Li, Yueli Zhu, Ting Shen, Kaicheng Li, Yaping Yan, Jun Tian, Zhirong Liu and Baorong Zhang
    Citation: Alzheimer's Research & Therapy 2021 13:40
  31. Current tasks measuring social cognition are usually ‘pen and paper’ tasks, have ceiling effects and include complicated test instructions that may be difficult to understand for those with cognitive impairmen...

    Authors: Lucy L. Russell, Caroline V. Greaves, Rhian S. Convery, Jennifer Nicholas, Jason D. Warren, Diego Kaski and Jonathan D. Rohrer
    Citation: Alzheimer's Research & Therapy 2021 13:39
  32. Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mi...

    Authors: Claudia Cicognola, Oskar Hansson, Philip Scheltens, Hlin Kvartsberg, Henrik Zetterberg, Charlotte E. Teunissen and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2021 13:38
  33. Synaptic failure is one of the principal events associated with cognitive dysfunction in Alzheimer’s disease (AD). Preservation of existing synapses and prevention of synaptic loss are promising strategies to ...

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2021 13:37

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:42

  34. β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer’s disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help strea...

    Authors: Elena Tsoy, Amelia Strom, Leonardo Iaccarino, Sabrina J. Erlhoff, Collette A. Goode, Anne-Marie Rodriguez, Gil D. Rabinovici, Bruce L. Miller, Joel H. Kramer, Katherine P. Rankin, Renaud La Joie and Katherine L. Possin
    Citation: Alzheimer's Research & Therapy 2021 13:36
  35. The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, ...

    Authors: Emma M. Coomans, Deborah N. Schoonhoven, Hayel Tuncel, Sander C. J. Verfaillie, Emma E. Wolters, Ronald Boellaard, Rik Ossenkoppele, Anouk den Braber, Wiep Scheper, Patrick Schober, Steven P. Sweeney, J. Michael Ryan, Robert C. Schuit, Albert D. Windhorst, Frederik Barkhof, Philip Scheltens…
    Citation: Alzheimer's Research & Therapy 2021 13:35
  36. Identification of genetic risk factors that are shared between Alzheimer’s disease (AD) and other traits, i.e., pleiotropy, can help improve our understanding of the etiology of AD and potentially detect new t...

    Authors: William P. Bone, Katherine M. Siewert, Anupama Jha, Derek Klarin, Scott M. Damrauer, Kyong-Mi Chang, Philip S. Tsao, Themistocles L. Assimes, Marylyn D. Ritchie and Benjamin F. Voight
    Citation: Alzheimer's Research & Therapy 2021 13:34
  37. Physical inactivity has been consistently linked to increased risk of cognitive decline; however, studies examining the impact of exercise interventions on cognition have produced inconsistent findings. Some o...

    Authors: Belinda M. Brown, Natalie Frost, Stephanie R. Rainey-Smith, James Doecke, Shaun Markovic, Nicole Gordon, Michael Weinborn, Hamid R. Sohrabi, Simon M. Laws, Ralph N. Martins, Kirk I. Erickson and Jeremiah J. Peiffer
    Citation: Alzheimer's Research & Therapy 2021 13:33
  38. Prominent activation of microglial immune/inflammatory processes is a characteristic feature of brains of patients with tauopathies including Alzheimer’s disease (AD), suggesting that neuroinflammation may be ...

    Authors: Yun-Beom Choi, Ambrose A. Dunn-Meynell, Michelle Marchese, Benjamin M. Blumberg, Deeya Gaindh, Peter C. Dowling and Wei Lu
    Citation: Alzheimer's Research & Therapy 2021 13:32
  39. APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer’s pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive symptoms in the presence ...

    Authors: Jagan A. Pillai, James Bena, Aaron Bonner-Jackson and James B. Leverenz
    Citation: Alzheimer's Research & Therapy 2021 13:31
  40. Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer’s disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestatio...

    Authors: Minesh Kapadia, M. Firoz Mian, Donglai Ma, Craig P. Hutton, Amber Azam, Klotilda Narkaj, Chuanhai Cao, Breanna Brown, Bernadeta Michalski, David Morgan, Paul Forsythe, Iva B. Zovkic, Margaret Fahnestock and Boris Sakic
    Citation: Alzheimer's Research & Therapy 2021 13:30
  41. White matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, in...

    Authors: Malo Gaubert, Catharina Lange, Antoine Garnier-Crussard, Theresa Köbe, Salma Bougacha, Julie Gonneaud, Robin de Flores, Clémence Tomadesso, Florence Mézenge, Brigitte Landeau, Vincent de la Sayette, Gaël Chételat and Miranka Wirth
    Citation: Alzheimer's Research & Therapy 2021 13:29
  42. The brain’s dynamic spontaneous neural activity and dynamic functional connectivity (dFC) are both important in supporting cognition, but how these two types of brain dynamics evolve and co-evolve in subjectiv...

    Authors: Lingyan Liang, Yueming Yuan, Yichen Wei, Bihan Yu, Wei Mai, Gaoxiong Duan, Xiucheng Nong, Chong Li, Jiahui Su, Lihua Zhao, Zhiguo Zhang and Demao Deng
    Citation: Alzheimer's Research & Therapy 2021 13:28
  43. Neuroimaging studies of autosomal dominant Alzheimer’s disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset....

    Authors: Justin S. Sanchez, Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Ana Baena, Yamile Bocanegra, David Aguillon, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, Liliana Ramirez-Gomez, Clara Vila-Castelar, Jairo E. Martinez, Joshua T. Fox-Fuller, Claudia Ramos, Martin Ochoa-Escudero, Sergio Alvarez…
    Citation: Alzheimer's Research & Therapy 2021 13:27
  44. Whether in the context of monitoring disease progression or in assessing the effects of interventions, a major challenge in dementia research is determining when an individual has undergone meaningful change i...

    Authors: Aja Louise Murray, Marlena Vollmer, Ian J. Deary, Graciela Muniz-Terrera and Tom Booth
    Citation: Alzheimer's Research & Therapy 2021 13:26
  45. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert
    Citation: Alzheimer's Research & Therapy 2021 13:25

    The original article was published in Alzheimer's Research & Therapy 2020 12:169

  46. Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new ap...

    Authors: Yadi Zhou, Jiansong Fang, Lynn M. Bekris, Young Heon Kim, Andrew A. Pieper, James B. Leverenz, Jeffrey Cummings and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2021 13:24
  47. The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer’s disease (AD) is difficult due to the overlaps of clinical symptoms. Structural magnetic resonance imaging (sMRI) presents distinct br...

    Authors: Qun Yu, Yingren Mai, Yuting Ruan, Yishan Luo, Lei Zhao, Wenli Fang, Zhiyu Cao, Yi Li, Wang Liao, Songhua Xiao, Vincent C. T. Mok, Lin Shi and Jun Liu
    Citation: Alzheimer's Research & Therapy 2021 13:23
  48. Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker cutoffs from immunoassays with low interlaboratory variability in diverse ethnic groups are necessary for their use in clinics and clinical trials. ...

    Authors: Sohee Moon, Sujin Kim, Sakulrat Mankhong, Seong Hye Choi, Manu Vandijck, Vesna Kostanjevecki, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Hee Jin Kim, Jae-Won Jang, Jin Yong Hong, Dong-Ho Park, Leslie M. Shaw…
    Citation: Alzheimer's Research & Therapy 2021 13:22